Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes
Infection and Drug Resistance · 2024-03 · Volume 17 · 819-843
DOI: 10.2147/idr.s431526 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Infection and Drug Resistance, 2024-03. Verfasst von Eden Axler und 1 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine, Department of Dermatology, New York, NY, 10021, USA. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 185 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Weill Cornell Medicine, Department of Dermatology, New York, NY, 10021, USA.
ORCID-Profile: Shari R Lipner
Zitieren
APA
Axler, E., & Lipner, S. R. (2024). Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes. Infection and Drug Resistance, Volume 17, 819-843. https://doi.org/10.2147/idr.s431526
Vancouver
Axler E, Lipner SR. Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes. Infection and Drug Resistance. 2024;Volume 17:819-843. doi:10.2147/idr.s431526
BibTeX
@article{Axler2024,
author = {Axler, Eden and Lipner, Shari R},
title = {Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes},
journal = {Infection and Drug Resistance},
year = {2024},
volume = {Volume 17},
pages = {819--843},
doi = {10.2147/idr.s431526}
}
EUVIMED